ezetimibe has been researched along with ST Elevated Myocardial Infarction in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bacchin, ASF; Bianco, HT; Caixeta, A; Damasceno, NRT; Fonseca, FA; França, CN; Izar, MCO; Mello, APQ; Moreira, FT; Neto, AMF; Pinto, LCS; Póvoa, RMS | 1 |
| Barthélémy, O; Brugier, D; Collet, JP; Guedeney, P; Kerneis, M; Lattuca, B; Mertens, E; Montalescot, G; Posson, J; Procopi, N; Sabouret, P; Salloum, T; Silvain, J; Sulman, D; Zeitouni, M | 1 |
| Geiling, JA; Haxhikadrija, P; Lauer, B; Makhmudova, U; Maloku, A; Möbius-Winkler, S; Otto, S; Römer, R; Samadifar, B; Schulze, PC; Weingärtner, O | 1 |
| Lei, LC; Li, GP; Peng, JJ; Ren, LH; Wang, ZY; Ye, HM; Zhao, B; Zhao, S | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Otsuki, H; Yamaguchi, J | 1 |
| Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM | 1 |
| Arashi, H; Endoh, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Alves, CMR; Berwanger, O; Bianco, HT; Caixeta, A; Carvalho, ACC; Damiani, LP; Fonseca, FAH; Fonseca, HA; França, CN; Izar, MC; Klassen, A; Maugeri, IML; Moreira, FT; Pinto, IM; Soriano Lopes, A; Szarf, G; Tavares, MFM | 1 |
| Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Maehara, A; Mintz, GS; Thayssen, P | 1 |
6 trial(s) available for ezetimibe and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction.
Topics: Aged; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Denmark; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Quinolines; Single-Blind Method; ST Elevation Myocardial Infarction; Survival Rate; Treatment Outcome | 2020 |
Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Non-ST Elevated Myocardial Infarction; Prospective Studies; Quinolines; ST Elevation Myocardial Infarction; Treatment Outcome | 2017 |
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My
Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enzyme-Linked Immunospot Assay; Ezetimibe; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Magnetic Resonance Imaging; Male; Metabolomics; Platelet Aggregation Inhibitors; Proteomics; Research Design; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Stroke Volume; T-Lymphocytes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Influence of Ezetimibe on Plaque Morphology in Patients with ST Elevation Myocardial Infarction Assessed by Optical Coherence Tomography: An OCTIVUS Sub-Study.
Topics: Coronary Artery Disease; Coronary Vessels; Ezetimibe; Humans; Plaque, Atherosclerotic; ST Elevation Myocardial Infarction; Tomography, Optical Coherence | 2020 |
3 other study(ies) available for ezetimibe and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.
Topics: Anticholesteremic Agents; Cardiology; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Practice Guidelines as Topic; Proprotein Convertase 9; ST Elevation Myocardial Infarction | 2022 |
Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Prospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Combined Modality Therapy; Critical Care; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Percutaneous Coronary Intervention; Quinolines; Risk Factors; ST Elevation Myocardial Infarction; Treatment Outcome | 2021 |